Typhoid poses a significant challenge in India, which has one of the highest burdens of the disease globally, making the implementation of cost-effective vaccination strategies essential. The success of typhoid vaccination, whether through clinical trials or large-scale public health programmes, depends on community acceptance. In the post-COVID-19 period, vaccine hesitancy and scepticism have emerged as key challenges to both vaccine trials and mass vaccination efforts. This study examines the barriers to and motivations for vaccine uptake during a mass vaccination campaign. We conducted 15 focus group discussions (FGDs) and five in-depth interviews (IDIs) with participants and guardians from a cluster-randomised typhoid vaccine trial in Vellore, India. Data collection occurred two months after the vaccination campaign in purposively selected low- and high-coverage areas. FGD categories were determined a priori based on age, gender, and vaccination status, while IDIs were conducted when FGDs were not feasible. Data were collected until thematic saturation was achieved. The interviews were audio-recorded, transcribed, and analysed using thematic analysis. Vaccination decisions were shaped by a combination of safety concerns, risk perceptions, and social influences. Key barriers included fears of long- and short-term adverse events, low perceived disease risk and consequently a reduced perceived need for vaccination, shifting attitudes toward new and adult vaccination following COVID-19, sociocultural beliefs, objections from household decision-makers, perceived lack of visible government endorsement and participation, and trust in alternative systems of medicine. The motivators included increased disease salience after the COVID-19 pandemic, increased perceived disease risk, positive influence from family members and peers, and trust in healthcare providers and professional recommendations. Study-related benefits, such as access to vaccines, follow-up, and free vaccination, operated bidirectionally, motivating many participants while raising concerns about vaccine quality among a few. In the post–COVID-19 era, vaccine availability alone does not ensure uptake. Vaccination programmes should actively engage household decision-makers, leverage trusted healthcare providers, address safety concerns and misconceptions surrounding new and free vaccines, and strengthen community trust alongside logistical planning.
Thomas et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: